FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.
You may also be interested in...
Review Of Reviews: Drug Review Profiles 2014
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2014.
Review Of Reviews: Drug Review Profiles 2014
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2014.
Piramal Hopes Depth Of Neuraceq Data Will Provide Contrast For Third Alzheimer’s Imaging Agent
Neuraceq will be the third entrant into the beta-amyloid imaging market, a space already limited by concerns about the clinical utility of PET scans in Alzheimer’s disease management.